MON-102 Nonclinical Development of AZP-531 (Livoletide): A Peptide Analog of Unacylated Ghrelin for the Treatment of Hyperphagia in Prader-Willi Syndrome

Lignende værker

• SUN-609 Livoletide (AZP-531), an Unacylated Ghrelin Analogue, Improves Hyperphagia and Food-Related Behaviors Both in Obese and Non-Obese People with Prader-Willi Syndrome
  af: Harisseh, Rania, et al.
  Udgivet: (2020)
• SUN-608 Juvenile Toxicity Study of Livoletide: A Peptide Analogue of Unacylated Ghrelin for the Treatment of Hyperphagia in Prader-Willi Syndrome
  af: Xu, Howard, et al.
  Udgivet: (2020)
• AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial
  af: Allas, Soraya, et al.
  Udgivet: (2018)
• SAT-100 Trial-in-Progress: ZEPHYR, a Pivotal Phase 2b/3 Randomized, Placebo-Controlled Study of Livoletide, a Novel Unacylated Ghrelin Analog, for the Treatment of Hyperphagia and Food-Related Behaviors in Patients with Prader-Willi Syndrome
  af: Allas, Soraya, et al.
  Udgivet: (2019)
• Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader–Willi syndrome
  af: Kuppens, R. J., et al.
  Udgivet: (2015)